Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
14.79 USD | -4.33% | -5.39% | +9.70% |
Financials (USD)
Sales 2024 * | 168M | Sales 2025 * | 299M | Capitalization | 1.49B |
---|---|---|---|---|---|
Net income 2024 * | -48M | Net income 2025 * | 58M | EV / Sales 2024 * | 8.71 x |
Net cash position 2024 * | 19.66M | Net cash position 2025 * | 70.24M | EV / Sales 2025 * | 4.73 x |
P/E ratio 2024 * |
-27.9
x | P/E ratio 2025 * |
25.8
x | Employees | 154 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 95.29% |
Latest transcript on Avadel Pharmaceuticals plc
1 day | -4.30% | ||
1 week | -4.49% | ||
Current month | -6.65% | ||
1 month | -20.03% |
Managers | Title | Age | Since |
---|---|---|---|
Gregory Divis
CEO | Chief Executive Officer | 57 | 17-01-02 |
Thomas McHugh
DFI | Director of Finance/CFO | 59 | 19-12-01 |
Scott Macke
COO | Chief Operating Officer | - | 14-08-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Eric Ende
BRD | Director/Board Member | 55 | 18-11-30 |
Gregory Divis
CEO | Chief Executive Officer | 57 | 17-01-02 |
Mark McCamish
BRD | Director/Board Member | 72 | 19-12-04 |
Date | Price | Change | Volume |
---|---|---|---|
24-06-05 | 14.76 | -4.53% | 535 872 |
24-06-04 | 15.46 | -1.28% | 869,208 |
24-06-03 | 15.66 | -1.82% | 648,315 |
24-05-31 | 15.95 | +1.21% | 738,608 |
24-05-30 | 15.76 | +1.09% | 1,100,938 |
Delayed Quote Nasdaq, June 05, 2024 at 12:41 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+9.70% | 1.49B | |
+43.39% | 750B | |
+34.11% | 606B | |
-6.33% | 356B | |
+18.78% | 326B | |
+6.56% | 286B | |
+18.08% | 246B | |
-3.44% | 213B | |
+11.35% | 213B | |
+2.15% | 167B |
- Stock Market
- Equities
- AVDL Stock